Literature DB >> 30411271

ASO Author Reflections: Low-Volume Sentinel Node Disease After Neoadjuvant Chemotherapy is Still an Indication for Axillary Dissection.

Tracy-Ann Moo1, Monica Morrow2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30411271      PMCID： PMC6622457          DOI： 10.1245/s10434-018-7000-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  5 in total

1.  Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer.

Authors:  G Cserni; D Gregori; F Merletti; A Sapino; M P Mano; A Ponti; S Sandrucci; B Baltás; G Bussolati
Journal:  Br J Surg       Date:  2004-10       Impact factor: 6.939

2.  Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?

Authors:  Tracy-Ann Moo; Marcia Edelweiss; Sabina Hajiyeva; Michelle Stempel; Monica Raiss; Emily C Zabor; Andrea Barrio; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2018-03-23       Impact factor: 5.344

3.  Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection.

Authors:  V J Kamath; R Giuliano; E L Dauway; A Cantor; C Berman; N N Ku; C E Cox; D S Reintgen
Journal:  Arch Surg       Date:  2001-06

4.  Intraoperative assessment of sentinel lymph nodes after neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Isabel T Rubio; Fernando Aznar; Jose Lirola; Vicente Peg; Jordi Xercavins
Journal:  Ann Surg Oncol       Date:  2009-09-24       Impact factor: 5.344

5.  A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy.

Authors:  Kimberly J Van Zee; Donna-Marie E Manasseh; Jose L B Bevilacqua; Susan K Boolbol; Jane V Fey; Lee K Tan; Patrick I Borgen; Hiram S Cody; Michael W Kattan
Journal:  Ann Surg Oncol       Date:  2003-12       Impact factor: 5.344
  5 in total
  1 in total

1.  Five-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1-4N1-3M0 Breast Cancer.

Authors:  Kelly M Herremans; Morgan P Cribbin; Andrea N Riner; Dan W Neal; Tracy L Hollen; Pamela Clevenger; Derly Munoz; Shannon Blewett; Fantine Giap; Paul G Okunieff; Nancy P Mendenhall; Julie A Bradley; William M Mendenhall; Raymond B Mailhot-Vega; Eric Brooks; Karen C Daily; Coy D Heldermon; Julia K Marshall; Mariam W Hanna; Mark M Leyngold; Sarah S Virk; Christiana M Shaw; Lisa R Spiguel
Journal:  Ann Surg Oncol       Date:  2021-08-07       Impact factor: 5.344
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.